Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) ...

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to ...

US pharma major Eli Lilly shares closed up 2.8%, while those of Adverum Biotechnologies dropped 2.4% to $4.28, on news of a ...

Adverum Biotechnologies ( ($ADVM) ) has shared an update. On October 24, 2025, Adverum Biotechnologies entered into a merger agreement with Eli ...

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Under the agreement, Lilly will gain control of Adverum’s lead product candidate, Ixo-vec, a Phase 3 gene therapy designed to treat wet age-related macular degeneration (wAMD) with a single ...